<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21645" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fatty Liver</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Antunes</surname>
            <given-names>Catiele</given-names>
          </name>
          <aff>Johns Hopkins Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Azadfard</surname>
            <given-names>Mohammadreza</given-names>
          </name>
          <aff>University at Buffalo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hoilat</surname>
            <given-names>Gilles J.</given-names>
          </name>
          <aff>University of Iowa Hospital &#x00026; Clinics</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catiele Antunes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammadreza Azadfard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gilles Hoilat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21645.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Non-alcoholic Fatty Liver Disease (NAFLD) or "Fatty Liver" corresponds to the presence of macrovesicular changes without inflammation (steatosis) and lobular inflammation in the absence of significant alcohol use. It can be divided into two subgroups: NAFL (Non-Alcoholic Fatty Liver) or simply Steatosis and NASH (Non-Alcoholic Steatohepatitis). NAFL is defined as hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning the hepatocytes. This activity reviews the cause of fatty liver and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the causes of fatty liver.</p></list-item><list-item><p>Assess&#x000a0;the pathophysiology of fatty liver.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment of fatty liver.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by fatty liver.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21645&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21645">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21645.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Non-alcoholic Fatty Liver Disease (NAFLD) or "Fatty Liver" corresponds to the presence of&#x000a0;macrovesicular changes without inflammation (steatosis) and lobular inflammation in the absence of significant alcohol use. It can be divided into&#x000a0;2 subgroups: Non-Alcoholic Fatty Liver (NAFL) or simply&#x000a0;Steatosis and Non-Alcoholic Steatohepatitis (NASH). NAFL is defined as hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning the hepatocytes. NASH is defined as hepatic steatosis and inflammation with hepatocyte injury (ballooning), Malloryhyaline, and mixed lymphocytic and neutrophilic inflammatory infiltrate in perivenular areas with or without fibrosis.<xref ref-type="bibr" rid="article-21645.r1">[1]</xref> It is important to note that NAFL is a spectrum, with NAFL being the mildest form and NASH and cirrhosis being at&#x000a0;the other end. NAFL or Steatosis and NASH could only be distinguished with histology and liver biopsy.<xref ref-type="bibr" rid="article-21645.r2">[2]</xref>.</p>
        <p>NAFLD is commonly associated with Metabolic Syndrome, obesity, diabetes, and hyperlipidemia. Nearly 80% of patients with Metabolic Syndrome have NAFLD.<xref ref-type="bibr" rid="article-21645.r3">[3]</xref><xref ref-type="bibr" rid="article-21645.r4">[4]</xref><xref ref-type="bibr" rid="article-21645.r5">[5]</xref></p>
      </sec>
      <sec id="article-21645.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Fat accumulates in the liver for several reasons. It most commonly involves increased delivery of free fatty acids to the liver, increased synthesis of fatty acids in the liver, decreased oxidation of FFA, or decreased synthesis or secretion of very-low-density lipoprotein.<xref ref-type="bibr" rid="article-21645.r6">[6]</xref><xref ref-type="bibr" rid="article-21645.r7">[7]</xref>&#x000a0;Oxidative stress in the hepatocytes can activate stellate cells and lead to the&#x000a0;production of collagen and inflammation. Other factors that may contribute to fatty liver include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The use of medications (eg, tamoxifen, amiodarone, methotrexate)</p>
          </list-item>
          <list-item>
            <p>Metabolic abnormalities (eg, glycogen storage disorders, homocystinuria)</p>
          </list-item>
          <list-item>
            <p>Alcohol</p>
          </list-item>
          <list-item>
            <p>Nutritional status (eg, total parenteral nutrition, severe malnutrition, overnutrition, or a starvation diet)</p>
          </list-item>
          <list-item>
            <p>Other health issues like Wilson disease and celiac sprue.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of NAFLD varies dramatically depending on the population being studied. It is estimated that the prevalence of NAFLD is 20% in the United States population and between 11.5% and 46% in the general population. By contrast, the prevalence of NASH is in the range of 2% and 3%.&#x000a0;The prevalence is higher in white men than white women, but there are no differences between Hispanic and African-American people<xref ref-type="bibr" rid="article-21645.r8">[8]</xref>.&#x000a0;Mean age at diagnosis is 50 years (range 16-80). It is more common in Hispanics when compared to Whites and more common in Whites than in Blacks. Obesity is a&#x000a0;well-known risk factor for NAFLD. In patients with severe obesity undergoing bariatric surgery, up to 90% are found to have NAFLD, and some even have cirrhosis. The same study also concluded that insulin resistance was the main predictor for NASH.<xref ref-type="bibr" rid="article-21645.r9">[9]</xref></p>
      </sec>
      <sec id="article-21645.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Current concepts point to insulin resistance as the primary metabolic defect leading to NAFLD. Insulin resistance increases the influx of free fatty acids into the liver. This happens due to the failure of insulin to suppress the hormone-sensitive lipase, causing more FFA to be released from the adipose tissue. Also, elevated insulin levels and insulin resistance promote continuous synthesis of triglycerides in the liver.&#x000a0;These 2 sources of triglycerides result in the accumulation of lipids in the hepatocytes, causing macrovesicular hepatic steatosis (see&#x000a0;<bold>Image.</bold>&#x000a0;Liver Biopsy, Hepatic Steatosis).<xref ref-type="bibr" rid="article-21645.r6">[6]</xref><xref ref-type="bibr" rid="article-21645.r10">[10]</xref>&#x000a0;Lipid accumulation in nonadipose tissue is a key factor for progressing insulin resistance, DM(Diabetes mellitus), and cardiovascular disease.<xref ref-type="bibr" rid="article-21645.r11">[11]</xref>&#x000a0;The current hypothesis is that NASH evolves from NAFLD caused by a second "hit." The evidence behind this second insult is inconclusive, but the most acceptable theories involve oxidative stress, specific cytokines, and lipopolysaccharides. Free fatty acids and hyperinsulinemia potentiate lipid peroxidation and the release of hydroxy-free radicals, directly injuring the hepatocytes by recruiting neuroinflammatory mediators. Chronic liver injury over time lead to activation of stellate cells, creating a potential for hepatic fibrosis. The diagnosis of NASH can only be established with a liver biopsy. Biopsy findings can reveal the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1: fatty liver alone; macrovesicular steatosis</p>
          </list-item>
          <list-item>
            <p>Type 2: fatty accumulation and lobar inflammation</p>
          </list-item>
          <list-item>
            <p>Type 3: fat accumulation and ballooning degeneration</p>
          </list-item>
          <list-item>
            <p>Type 4: fat accumulation, ballooning degeneration, and either Mallory hyaline or fibrosis.</p>
          </list-item>
        </list>
        <p>Type 3 and Type 4 are NASH by definition.</p>
      </sec>
      <sec id="article-21645.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically, the fatty liver reveals fat accumulation in the central (centrilobular) zone. Universally, one notes the presence of macrovesicular steatosis with the liver cells containing several large fat droplets that displace the nucleus. Sometimes, the lipid deposits may be released due to the rupture of the overtly distended liver cells, which produces lipogranulomas composed chiefly of macrophages and occasional lymphocytes.<xref ref-type="bibr" rid="article-21645.r12">[12]</xref>&#x000a0;See <bold>Image.</bold> Fatty Liver Disease.</p>
      </sec>
      <sec id="article-21645.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients are usually asymptomatic, and "fatty liver" is usually an incidental finding on imaging done for other purposes. When patients do&#x000a0;have symptoms, they are usually nonspecific, constitutional or right upper quadrant discomfort. It is important to obtain detailed alcohol use, review past medical history, family history, current and past prescription medications, and use of over-the-counter drugs or supplements. The history should include diet, physical activity, weight change ( weight gain of over 18 kg in 2-3 years), and evaluation for associated conditions like obesity, hyperlipidemia, and diabetes ).<xref ref-type="bibr" rid="article-21645.r13">[13]</xref></p>
      </sec>
      <sec id="article-21645.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Laboratory studies lack specificity and cannot distinguish NASH from NAFLD; however, initial evaluation should include an assessment of a complete hepatic panel, lipid panel, and iron.&#x000a0;Lab tests may be used to evaluate insulin resistance, which includes the Homeostasis Model Assessment (normal value&#x0003c;3.99)<xref ref-type="bibr" rid="article-21645.r14">[14]</xref>&#x000a0;and The Quantitative Insulin Sensitivity Check Index&#x000a0;<xref ref-type="bibr" rid="article-21645.r15">[15]</xref>.&#x000a0;Lab tests to rule out viral hepatitis and Hemochromatosis should be ordered. Suppose the patient has elevated liver enzymes chronically or has a family history of cirrhosis. In that case, additional tests, like an antinuclear antibody, smooth muscle antibody,a1-antitrypsin, ceruloplasmin, and thyroid-stimulating hormone levels, should be considered.<xref ref-type="bibr" rid="article-21645.r16">[16]</xref><xref ref-type="bibr" rid="article-21645.r13">[13]</xref>&#x000a0;Patients with alcoholic liver disease may have or have not elevated serum aminotransferase levels. The absolute level of liver enzyme elevation is not related to the severity of alcohol liver disease. Still, the pattern of elevation in liver enzymes helps make a diagnosis of alcoholic liver disease. AST level is typically&#x000a0;2 to&#x000a0;3 times greater than ALT in alcoholic liver injury. Also, these patients have an elevated serum gamma-glutamyltranspeptidase.<xref ref-type="bibr" rid="article-21645.r17">[17]</xref>&#x000a0;Imaging studies play a key role in the diagnosis of NAFLD. The mainstay is ultrasonography; it is the least invasive and relatively inexpensive. The sensitivity of an ultrasound to detect NAFLD is in the range of 60% to 90%, with a specificity of around 90%. Unenhanced abdominal computed tomography and magnetic resonance are alternatives but more costly and less significantly&#x000a0;superior to ultrasonography.<xref ref-type="bibr" rid="article-21645.r18">[18]</xref><xref ref-type="bibr" rid="article-21645.r3">[3]</xref><xref ref-type="bibr" rid="article-21645.r19">[19]</xref></p>
        <p>Diagnosis of NASH requires a liver biopsy; however, not all patients with NAFLD require a liver biopsy. The decision to proceed with histological examination depends on risk factors, laboratory workup, and disease severity. According to the 2012 guidelines from the American Association for the Study of Liver Disease, liver biopsy should be reserved for subjects who benefit, for subjects with potentially competing diagnoses, and for children with either an unclear diagnosis or in whom consideration is being given for medication. Liver biopsy has a moderate risk of complications and is invasive, subject to sampling error, and expensive.<xref ref-type="bibr" rid="article-21645.r20">[20]</xref></p>
      </sec>
      <sec id="article-21645.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Lifestyle modifications and weight loss are the mainstays of the treatment. Treatment also involves glycemic and lipid control. For patients with significant obesity, gastric bypass or other weight loss surgical modalities should be considered. Weight loss is proven to reduce hepatic steatosis. The evidence suggests that a loss of 3% to 5% of body weight is necessary to notice an improvement in steatosis. Still, a greater loss (up to 10%) is necessary to improve necroinflammation.<xref ref-type="bibr" rid="article-21645.r21">[21]</xref><xref ref-type="bibr" rid="article-21645.r22">[22]</xref><xref ref-type="bibr" rid="article-21645.r23">[23]</xref>&#x000a0;Patients should abstain from alcohol or hepatotoxic drugs. Pharmacological options include Metformin, Vitamin E, fish oil, Orlistat (an inhibitor of gastric and pancreatic lipase), and Sibutramine. It is important to notice that the evidence behind these pharmacological modalities is weak. Three Cochrane reviews found insufficient evidence to support using bile acids (ursodeoxycholic acid), antioxidant supplements, metformin, or thiazolidinedione in the absence of diabetes in patients with nonalcoholic fatty liver disease.<xref ref-type="bibr" rid="article-21645.r24">[24]</xref><xref ref-type="bibr" rid="article-21645.r25">[25]</xref>Studies have shown that metformin does not significantly affect liver histology; therefore, its use is only recommended if there is another indication. Vitamin E is currently&#x000a0;only recommended for non-diabetic patients with biopsy-proven NASH. Pioglitazone can be used to&#x000a0;treat patients with biopsy-proven steatohepatitis, but its long-term effects are not known.&#x000a0;A randomized controlled trial of 247 adults with nonalcoholic steatohepatitis found improvement in AST and ALT levels with the use of vitamin E and pioglitazone but no improvement in fibrosis.<xref ref-type="bibr" rid="article-21645.r26">[26]</xref>&#x000a0;For patients with advanced disease and cirrhosis, liver transplantation might have to be considered.</p>
      </sec>
      <sec id="article-21645.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis for fatty liver include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Viral Hepatitis</p>
          </list-item>
          <list-item>
            <p>Alcoholic hepatitis</p>
          </list-item>
          <list-item>
            <p>Alpha1 Antitrypsin Deficiency</p>
          </list-item>
          <list-item>
            <p>Primary sclerosing cholangitis</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Primary biliary cholangitis</p>
          </list-item>
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>patients with NAFL (Non-alcoholic fatty liver disease )have 26 % higher health care costs in 5-year follow-up.<xref ref-type="bibr" rid="article-21645.r27">[27]</xref></p>
      </sec>
      <sec id="article-21645.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The complications that can manifest with fatty liver are as follow:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cirrhosis</p>
          </list-item>
          <list-item>
            <p>Ascites</p>
          </list-item>
          <list-item>
            <p>Esophageal varices</p>
          </list-item>
          <list-item>
            <p>Liver failure</p>
          </list-item>
          <list-item>
            <p>Liver cancer</p>
          </list-item>
          <list-item>
            <p>Type 2 diabetes</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative and rehabilitation care considerations for fatty liver include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should be tested for other causes of liver injury like hepatitis B and offer vaccination</p>
          </list-item>
          <list-item>
            <p>All drugs that affect the liver must be discontinued</p>
          </list-item>
          <list-item>
            <p>The disease progression should be monitored for signs of liver dysfunction like ascites, palmar erythema, decreasing levels of albumin, and elevated levels of INR.</p>
          </list-item>
          <list-item>
            <p>Levels of blood alcohol should be checked regularly to check for abstinence from alcohol.</p>
          </list-item>
          <list-item>
            <p>Patients with end-stage&#x000a0;liver disease should be screened for liver cancer and gastroesophageal varices.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Consultations that are typically requested for patients with this condition include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>General and bariatric surgeon</p>
          </list-item>
          <list-item>
            <p>Radiologist for TIPS</p>
          </list-item>
          <list-item>
            <p>Gastroenterologist</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Considerations for deterrence and patient education for fatty liver include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The patient should refrain from alcohol.</p>
          </list-item>
          <list-item>
            <p>Malnutrition is common in these patients, so a dietary consult should be obtained. A low-fat diet and weight loss&#x000a0;is&#x000a0;recommended.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Participating in a regular exercise program is highly recommended.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21645.s16" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Although the overall risk of cirrhosis due to NAFLD is modest, certain groups are at particular risk. Important risk factors for NASH are obesity, diabetes, and advanced age.&#x000a0;</p>
      </sec>
      <sec id="article-21645.s17" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Fatty liver is on the rise in the US primarily because of an increase in obesity, type 2 diabetes, and consumption of alcohol. The condition can be reversed if detected early but requires an interprofessional approach. Education of the patient is vital to ensure that there is complete abstinence from alcohol. For those who do not remain compliant, end-stage liver disease can develop, which carries high morbidity and mortality. The nurse should also emphasize the importance of lifestyle changes and a healthy diet. Exercise and a healthy weight can help reverse the disorder and markedly improve the quality of life. The pharmacist must be closely involved in the management of these patients because several studies show that the use of oral hypoglycemics and lipid-lowering&#x000a0;agents may help lower the risk of heart disease. A bariatric surgery consult may be helpful for patients who cannot lose weight with conservative measures. There is evidence showing that appropriate weight loss surgery can significantly lower the risk of diabetes and heart disease.<xref ref-type="bibr" rid="article-21645.r21">[21]</xref><xref ref-type="bibr" rid="article-21645.r28">[28]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Several studies show that the prognosis is excellent if there is early intervention before the onset of fibrosis. However, if the treatment is delayed and end-stage&#x000a0;liver disease develops, the prognosis is poor. To reduce the morbidity of fatty liver, evidence suggests that one should adopt an aggressive and interprofessional strategy for managing obesity, diabetes, and metabolic syndrome.<xref ref-type="bibr" rid="article-21645.r29">[29]</xref><xref ref-type="bibr" rid="article-21645.r12">[12]</xref><xref ref-type="bibr" rid="article-21645.r30">[30]</xref></p>
      </sec>
      <sec id="article-21645.s18">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21645&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21645">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/fatty-liver/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21645">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21645/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21645">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21645.s19">
        <fig id="article-21645.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Fatty Liver Disease. Steatosis seen histologically as lipidic droplets (microvescicular) or a large intracytoplasmic vacuole (macrovescicular). Steatosis is quantified as a percentage of altered hepatocytes in all fields. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="liver04" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-21645.s20">
        <fig id="article-21645.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Liver Biopsy, Hepatic Steatosis. In this field, a group of hepatocytes (yellow dashes) is trapped in an altered portal tract due to long-standing hepatitis. Bile ducts are fragmented and multiple. Most of the small cells surrounding the portal tract are lymphocytes. Contributed by F Farci, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="liver03" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21645.s21">
        <title>References</title>
        <ref id="article-21645.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Janney</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Di Bisceglie</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>2467</fpage>
            <page-range>2467-74</page-range>
            <pub-id pub-id-type="pmid">10484010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tadkod</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hepburn</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schade</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic fatty liver disease: diagnosis and management.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-42</page-range>
            <pub-id pub-id-type="pmid">23939604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tovoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Napoli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Serio</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ferri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolondi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>14</day>
            <volume>24</volume>
            <issue>30</issue>
            <fpage>3361</fpage>
            <page-range>3361-3373</page-range>
            <pub-id pub-id-type="pmid">30122876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiavo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Busetto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cesaretti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zelber-Sagi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Iannelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Nutritional issues in patients with obesity and cirrhosis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Aug</month>
            <day>14</day>
            <volume>24</volume>
            <issue>30</issue>
            <fpage>3330</fpage>
            <page-range>3330-3346</page-range>
            <pub-id pub-id-type="pmid">30122874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seitz</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cortez-Pinto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gual</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lackner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mathurin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Szabo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Alcoholic liver disease.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2018</year>
            <month>Aug</month>
            <day>16</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>16</fpage>
            <pub-id pub-id-type="pmid">30115921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cleveland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bandy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>VanWagner</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.</article-title>
            <source>Clin Liver Dis (Hoboken)</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>98</fpage>
            <page-range>98-104</page-range>
            <pub-id pub-id-type="pmid">30147867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Anoop</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pradeepa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Body fat, metabolic syndrome and hyperglycemia in South Asians.</article-title>
            <source>J Diabetes Complications</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>1068</fpage>
            <page-range>1068-1075</page-range>
            <pub-id pub-id-type="pmid">30115487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angulo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>GI epidemiology: nonalcoholic fatty liver disease.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2007</year>
            <month>Apr</month>
            <day>15</day>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>883</fpage>
            <page-range>883-9</page-range>
            <pub-id pub-id-type="pmid">17402991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>1103</fpage>
            <page-range>1103-1115</page-range>
            <pub-id pub-id-type="pmid">30113367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?</article-title>
            <source>BMC Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>24</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <pub-id pub-id-type="pmid">30139362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>The liver and the waistline: Fifty years of growth.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>24 Suppl 3</volume>
            <fpage>S105</fpage>
            <page-range>S105-18</page-range>
            <pub-id pub-id-type="pmid">19799688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoo</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Jun</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yeon</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>JH</given-names>
              </name>
              <collab>the Korean Association for the Study of the Liver (KASL)-Korea Nonalcoholic fatty liver Study Group (KNSG)</collab>
            </person-group>
            <article-title>Recent research trends and updates on nonalcoholic fatty liver disease.</article-title>
            <source>Clin Mol Hepatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">30086613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loria</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adinolfi</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Bellentani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bugianesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grieco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fargion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loguercio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lonardo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marchesini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marra</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Persico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prati</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baroni</surname>
                <given-names>GS</given-names>
              </name>
              <collab>NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato</collab>
            </person-group>
            <article-title>Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.</article-title>
            <source>Dig Liver Dis</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-82</page-range>
            <pub-id pub-id-type="pmid">20171943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matthews</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Hosker</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rudenski</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Treacher</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.</article-title>
            <source>Diabetologia</source>
            <year>1985</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>412</fpage>
            <page-range>412-9</page-range>
            <pub-id pub-id-type="pmid">3899825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nambi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mather</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Follmann</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quon</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>7</issue>
            <fpage>2402</fpage>
            <page-range>2402-10</page-range>
            <pub-id pub-id-type="pmid">10902785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratziu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bellentani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cortez-Pinto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marchesini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A position statement on NAFLD/NASH based on the EASL 2009 special conference.</article-title>
            <source>J Hepatol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>372</fpage>
            <page-range>372-84</page-range>
            <pub-id pub-id-type="pmid">20494470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torruellas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Medici</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of alcoholic liver disease.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Sep</month>
            <day>07</day>
            <volume>20</volume>
            <issue>33</issue>
            <fpage>11684</fpage>
            <page-range>11684-99</page-range>
            <pub-id pub-id-type="pmid">25206273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosmalski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mokros</surname>
                <given-names>&#x00141;</given-names>
              </name>
              <name>
                <surname>Kuna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Witusik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pietras</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease.</article-title>
            <source>Cent Eur J Immunol</source>
            <year>2018</year>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <page-range>231-239</page-range>
            <pub-id pub-id-type="pmid">30135638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agganis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sepe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Liver enzymes: No trivial elevations, even if asymptomatic.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>85</volume>
            <issue>8</issue>
            <fpage>612</fpage>
            <page-range>612-617</page-range>
            <pub-id pub-id-type="pmid">30102591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ratziu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Charlotte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Heurtier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gombert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giral</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grimaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capron</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Poynard</surname>
                <given-names>T</given-names>
              </name>
              <collab>LIDO Study Group</collab>
            </person-group>
            <article-title>Sampling variability of liver biopsy in nonalcoholic fatty liver disease.</article-title>
            <source>Gastroenterology</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>128</volume>
            <issue>7</issue>
            <fpage>1898</fpage>
            <page-range>1898-906</page-range>
            <pub-id pub-id-type="pmid">15940625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Sch&#x000f6;nfels</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beckmann</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ahrens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>R&#x000f6;cken</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szymczak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hampe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schafmayer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score).</article-title>
            <source>Surg Obes Relat Dis</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>1607</fpage>
            <page-range>1607-1616</page-range>
            <pub-id pub-id-type="pmid">30146425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loman</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Saavedra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rector</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis.</article-title>
            <source>Nutr Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>76</volume>
            <issue>11</issue>
            <fpage>822</fpage>
            <page-range>822-839</page-range>
            <pub-id pub-id-type="pmid">30113661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alkhouri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poordad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lawitz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes.</article-title>
            <source>Hepatol Commun</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>7</issue>
            <fpage>778</fpage>
            <page-range>778-785</page-range>
            <pub-id pub-id-type="pmid">30027137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lirussi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Azzalini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Orando</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Angelico</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Jan</month>
            <day>24</day>
            <volume>2007</volume>
            <issue>1</issue>
            <fpage>CD004996</fpage>
            <pub-id pub-id-type="pmid">17253535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Angelico</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Burattin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alessandri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Del Ben</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lirussi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2007</year>
            <month>Jan</month>
            <day>24</day>
            <issue>1</issue>
            <fpage>CD005166</fpage>
            <pub-id pub-id-type="pmid">17253544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanyal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kowdley</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diehl</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Neuschwander-Tetri</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Lavine</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tonascia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Unalp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van Natta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brunt</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Robuck</surname>
                <given-names>PR</given-names>
              </name>
              <collab>NASH CRN</collab>
            </person-group>
            <article-title>Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>May</month>
            <day>06</day>
            <volume>362</volume>
            <issue>18</issue>
            <fpage>1675</fpage>
            <page-range>1675-85</page-range>
            <pub-id pub-id-type="pmid">20427778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baumeister</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lzke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Flessa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alte</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation.</article-title>
            <source>Gastroenterology</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-94</page-range>
            <pub-id pub-id-type="pmid">18005961</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esquivel</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armando</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lascano</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Foscarini</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?</article-title>
            <source>Obes Surg</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>4022</fpage>
            <page-range>4022-4033</page-range>
            <pub-id pub-id-type="pmid">30121855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coates</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Nuts and Cardiovascular Disease Prevention.</article-title>
            <source>Curr Atheroscler Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>09</day>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">30094487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sigler</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Congdon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease.</article-title>
            <source>Clin Med Insights Gastroenterol</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1179552218787502</fpage>
            <pub-id pub-id-type="pmid">30013416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezaian</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Abtahi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>External fixator in management of fractures and leg lengthening.</article-title>
            <source>Orthop Rev</source>
            <year>1986</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-8</page-range>
            <pub-id pub-id-type="pmid">3453434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21645.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Corvec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farrugia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nguyen-Khac</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>R&#x000e9;gimbeau</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dharhri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Khamphommala</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gautier</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Le Berre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bronowicki</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Brunaud</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mar&#x000e9;chal</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blanchet</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Frering</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Delwaide</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kohnen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haumann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delvenne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sarfati-Lebreton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tariel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toullec</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boursier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bedossa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gual</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anty</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iannelli</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Blood-based MASH diagnostic in candidates for bariatric surgery using mid-infrared spectroscopy: a European multicenter prospective study.</article-title>
            <source>Sci Rep</source>
            <year>2024</year>
            <month>Nov</month>
            <day>02</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>26452</fpage>
            <pub-id pub-id-type="pmid">39488538</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
